arrow
D

David Anz

University Hospital, LMU Munich
H指数:29
被引数:3,610

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Early mortality in atezolizumab/bevacizumab for HCC is associated with impaired liver function and alterations of systemic immunity

阿特珠单抗/贝伐珠单抗治疗肝细胞癌的早期死亡率与肝功能受损及全身免疫改变相关

2025-07-010
OAAI
Innate Immune Activation Is a Strong Suppressor of CCL22 and Impedes Regulatory T Cell-Dendritic Cell Interaction

固有免疫激活是CCL22的强效抑制因子,并阻碍调节性T细胞-树突状细胞相互作用

2025-03-260
OAAI
Dominant immune tolerance in the intestinal tract imposed by RelB-dependent migratory dendritic cells regulates protective type 2 immunity

依赖RelB的迁移树突状细胞在肠道中施加的显性免疫耐受调节保护性2型免疫

2024-10-230
OAAI
Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia

突变特异性CAR T细胞精准治疗高危慢性淋巴细胞白血病IGLV3-21R110

2024-02-024
OAAI
Neomorphic DNA-binding enables tumor-specific therapeutic gene expression in fusion-addicted childhood sarcoma
2022-10-133
OAAI
Presence of regulatory T-cells in endometrial cancer predicts poorer overall survival and promotes progression of tumor cells

子宫内膜癌中调节性T细胞的存在预示着较差的总生存期并促进肿瘤细胞的进展

2022-09-137
OAAI
CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes
2019-03-25155
OAAI